Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
NCT ID: NCT00096473
Last Updated: 2011-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
229 participants
INTERVENTIONAL
2001-01-31
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
NCT00711204
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
NCT00934375
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
NCT00630851
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
NCT00478205
Memory Impairment Study (Mild Cognitive Impairment Study)
NCT00000173
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have not been treated by any medication for Alzheimer's Disease in past 3 months
* Live in community or Assisted Living Facility
* Healthy or with chronic diseases that are medically controlled or stabilized
* Able to swallow tablets
Exclusion Criteria
* Dementia caused by organic diseases other than Alzheimer's Disease
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Eisai Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Richardson, Ph.D.
Role: STUDY_DIRECTOR
Eisai Inc.
Honglan Li, Ph.D.
Role: STUDY_DIRECTOR
Eisai Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northport, Alabama, United States
Phoenix, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
San Francisco, California, United States
Santa Monica, California, United States
Torrance, California, United States
Denver, Colorado, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
North Miami, Florida, United States
St. Petersburg, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Springfield, Massachusetts, United States
Long Branch, New Jersey, United States
Piscataway, New Jersey, United States
New Hyde Park, New York, United States
Greenville, North Carolina, United States
Raleigh, North Carolina, United States
Centerville, Ohio, United States
Oklahoma City, Oklahoma, United States
Medford, Oregon, United States
Portland, Oregon, United States
Jenkintown, Pennsylvania, United States
Austin, Texas, United States
Houston, Texas, United States
Randwick, New South Wales, Australia
Brisbane, Queensland, Australia
Woodville South, South Australia, Australia
Heidelberg West, Victoria, Australia
Nedlands, Western Australia, Australia
Toronto, Ontario, Canada
Hôpital Broca-La Rochefoucauld
Paris, , France
Belfast, , Ireland
Saint Leonards-on-Sea, East Sussex, United Kingdom
West End, Southampton, United Kingdom
Swindon, Wilshire, United Kingdom
Bath, , United Kingdom
Blackpool, , United Kingdom
Bradford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2020-A001-315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.